Načítá se...
Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...
Uloženo v:
| Vydáno v: | Pharmaceuticals (Basel) |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7766528/ https://ncbi.nlm.nih.gov/pubmed/33339404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13120470 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|